Skip to main content

Molnupiravir use while Breastfeeding

Medically reviewed by Drugs.com. Last updated on Dec 28, 2023.

Drugs containing Molnupiravir: Lagevrio

Molnupiravir Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the use of molnupiravir during breastfeeding. Breastfeeding is not recommended during treatment and for 4 days after the last dose of molnupiravir.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Nirmatrelvir, Remdesevir

Substance Identification

Substance Name

Molnupiravir

CAS Registry Number

2492423-29-5

Drug Class

Breast Feeding

Lactation

Milk, Human

Antiviral Agents

Nucleosides

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.